Pemigatinib in the Treatment of Metastatic, Inflammatory Triple-Negative Breast Cancer With FGFR2 Rearrangement: A Case Report and Review of the Literature
JCO Precision Oncology · 2026-08 · 10 (8)
DOI: 10.1200/po-25-00628 ↗Kurz gefasst
Fallbericht in der Zeitschrift JCO Precision Oncology, 2026-08. Verfasst von Nihaal Reddy und 2 weiteren Autor:innen. Beteiligte Einrichtung: UC San Diego Health, San Diego, CA. Die Arbeit nennt 17 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- UC San Diego Health, San Diego, CA.
- Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Irvine, CA.
ORCID-Profile: Nihaal Reddy, Rebecca Shatsky
Zitieren
APA
Reddy, N., Vasiljevic, K., & Shatsky, R. (2026). Pemigatinib in the Treatment of Metastatic, Inflammatory Triple-Negative Breast Cancer With FGFR2 Rearrangement: A Case Report and Review of the Literature. JCO Precision Oncology, 10(8). https://doi.org/10.1200/po-25-00628
Vancouver
Reddy N, Vasiljevic K, Shatsky R. Pemigatinib in the Treatment of Metastatic, Inflammatory Triple-Negative Breast Cancer With FGFR2 Rearrangement: A Case Report and Review of the Literature. JCO Precision Oncology. 2026;10(8). doi:10.1200/po-25-00628
BibTeX
@article{Reddy2026,
author = {Reddy, Nihaal and Vasiljevic, Katarina and Shatsky, Rebecca},
title = {Pemigatinib in the Treatment of Metastatic, Inflammatory Triple-Negative Breast Cancer With FGFR2 Rearrangement: A Case Report and Review of the Literature},
journal = {JCO Precision Oncology},
year = {2026},
volume = {10},
number = {8},
doi = {10.1200/po-25-00628}
}
EUVIMED